Surmodics is making a strategic addition to its portfolio of hemocompatible and biocompatible surface technologies through its acquisition of Alta Biomed.
Financial details of the transaction were not disclosed.
The acquisition adds Alta’s PzF thin-film surface modification technology to Surmodics' repertoire. This adds an established anti-thrombotic, anti-inflammatory, and pro-healing option that joins the Horsham, PA-based company’s existing hemocompatible portfolio.
“As medical device innovation advances in neuromodulation, brain-computer interfaces, neurovascular, structural heart, and venous and arterial technologies, engineers and scientists need a broader range of surface technology options to address increasingly complex blood-contacting applications," said Charlie Olson, president of coatings, biomaterials, and catheter technologies at Surmodics. “PzF gives our customers another proven thin-film surface modification to consider as they develop the next generation of devices.”
PzF is an ultra-thin polymer surface modification technology designed to enhance hemocompatibility for blood and tissue-contacting medical devices and materials. With more than 20 years of history in medical device applications, PzF has received six FDA clearances and one PMA approval and is commercialized today in cardiovascular and embolization technologies. The technology can be applied to a variety of substrates ranging from metals, polymers, medical fabrics, and even tissue. Device applications include stents, grafts, catheters, filters, nitinol devices, ePTFE devices, and PET/polyester materials.
The acquisition also expands Surmodics' analytical testing capabilities. Alta's Carlsbad, CA, facility brings established expertise in hemocompatibility and particulate testing, including coating integrity assessment, acute particulate testing, and dynamic human blood loop testing used to compare coated and uncoated devices.
Surmodics has assumed Alta's ongoing operations in Carlsbad. The location expands the company’s geographic footprint and provides a West Coast presence closer to many medical device companies in California and the surrounding region. Existing Alta programs will continue as the company's PzF surface modification and testing capabilities are integrated into the broader Surmodics organization.
“This acquisition is a natural and exciting next step for our team. Joining Surmodics provides the scale, established leadership, and global access to reach more patients with our advanced coating technologies,” said Chris Nocera, VP of engineering at Alta Biomed, who will lead the Carlsbad site.
Surmodics said the acquisition further advances its strategy to build a differentiated portfolio of coating and surface modification technologies, specialty biomaterials, and technical services that can support medical device companies from early feasibility and technology selection through testing, process development, and commercialization.